The US FDA has approved Bristol Myers Squibb’s new oral medicine, Cobenfy, for treating schizophrenia in adults. This approval introduces a novel pharmacological approach after more than 30 years. The drug will be available by late October at $1,850 per month before insurance and rebates. Clinical trials have shown significant improvement in symptoms compared to a placebo.
Related Posts
Sensex tumbles 1,018 points as Trump tariffs take toll
- staff
- February 12, 2025
- 0
On Tuesday, the sensex and Nifty closed lower for the fifth straight session due to weak global and domestic cues. Trump’s tariffs and ongoing US […]
S&P, Nasdaq log worst quarterly slumps in years
- staff
- April 1, 2025
- 0
S&P 500 and Nasdaq closed their worst quarter in years due to investor anxiety over Trump’s tariff agenda. Big tech suffered significant losses, with Tesla […]
‘Go for gold’: Why Goldman Sachs believes gold has the ‘highest potential’ for a near-term price hike
Goldman Sachs anticipates gold prices reaching $2,700 by early 2025. The bank predicts weaker trends in oil, gas, and industrial metals like copper and aluminum, […]